-
![Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers](/abs-image/US/2014/08/26/US08815945B2/abs.jpg.150x150.jpg)
1.发明授权Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers 有权使用双[硫代酰肼]化合物如elesclomol用于治疗癌症公开(公告)号：US08815945B2
公开(公告)日：2014-08-26
申请号：US13642275
申请日：2011-04-20
申请人： Masazumi Nagai , Ronald K. Blackman , Patricia E. Rao , Yumiko Wada , Keizo Koya
发明人： Masazumi Nagai , Ronald K. Blackman , Patricia E. Rao , Yumiko Wada , Keizo Koya
IPC分类号： A61K45/06 , A61K31/19 , A61K31/337
CPC分类号： A61K31/30 , A61K31/00 , A61K31/16 , A61K31/18 , A61K31/19 , A61K31/195 , A61K31/28 , A61K31/337 , A61K31/555 , A61K45/06 , A61K2300/00
摘要： Improved cancer treatments with bis[thiohydrazide amide] compounds such as elesclomol, in particular for identifying patient populations that would benefit from such treatments.
摘要翻译： 改进的双[硫代酰肼]化合物如elesclomol的癌症治疗，特别是用于鉴定将受益于这种治疗的患者群体。
-
![USE OF BIS [THIOHYDRAZIDE AMIDE] COMPOUNDS SUCH AS ELESCLOMOL FOR TREATING CANCERS](/abs-image/US/2013/06/13/US20130150440A1/abs.jpg.150x150.jpg)
2.发明申请USE OF BIS [THIOHYDRAZIDE AMIDE] COMPOUNDS SUCH AS ELESCLOMOL FOR TREATING CANCERS 有权使用BIS [硫羟酰胺酰胺]化合物作为ELESCLOMOL治疗癌症公开(公告)号：US20130150440A1
公开(公告)日：2013-06-13
申请号：US13642275
申请日：2011-04-20
申请人： Masazumi Nagai , Ronald K. Blackman , Patricia E. Rao , Yumiko Wada , Keizo Koya
发明人： Masazumi Nagai , Ronald K. Blackman , Patricia E. Rao , Yumiko Wada , Keizo Koya
CPC分类号： A61K31/30 , A61K31/00 , A61K31/16 , A61K31/18 , A61K31/19 , A61K31/195 , A61K31/28 , A61K31/337 , A61K31/555 , A61K45/06 , A61K2300/00
摘要： Improved cancer treatments with bis[thiohydrazide amide] compounds such as elesclomol, in particular for identifying patient populations that would benefit from such treatments.
摘要翻译： 改进的双[硫代酰肼]化合物如elesclomol的癌症治疗，特别是用于鉴定将受益于这种治疗的患者群体。
-
3.发明授权Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor 有权使用Hsp90抑制化合物和EGFR抑制剂的组合进行癌症治疗公开(公告)号：US09205086B2
公开(公告)日：2015-12-08
申请号：US13642068
申请日：2011-04-19
IPC分类号： A61K31/44 , A61K31/517 , A61K31/4196 , A61K31/675
CPC分类号： A61K31/4196 , A61K31/517 , A61K31/675 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical combination comprising an EGFR inhibitor and an Hsp90 inhibitor according to the following formulae (I) or (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof using pharmaceutical combinations disclosed herein.
摘要翻译： 包含EGFR抑制剂和根据下式（I）或（Ia）的互变异构体或其药学上可接受的盐的Hsp90抑制剂的药物组合，其中结构式中的变量在本文中定义。 还提供了使用本文公开的药物组合治疗有需要的受试者的增殖性病症的方法。
-
4.发明申请PRESELECTION OF SUBJECTS FOR THERAPEUTIC TREATMENT WITH ELESCLOMOL BASED ON HYPOXIC STATUS 审中-公开基于HYPOXIC状态的ELESCLOMOL治疗方案的选择公开(公告)号：US20140113972A1
公开(公告)日：2014-04-24
申请号：US14141883
申请日：2013-12-27
申请人： Ronald K. Blackman , Vojo Vukovic
发明人： Ronald K. Blackman , Vojo Vukovic
IPC分类号： A61K31/166 , G01N33/574 , C12Q1/68
CPC分类号： A61K31/166 , A61K31/165 , C12Q1/6886 , G01N33/57484
摘要： The present invention provides methods for the preselection of a subject for therapeutic treatment with elesclomol based on modulated levels of hypoxia in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with elesclomol based on modulated levels of lactate dehydrogenase (LDH). The invention also provides methods for treating cancer in a subject by administering an effective amount of elesclomol to the subject, wherein the subject has a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention.
摘要翻译： 本发明提供了基于受试者中调节的缺氧水平预先选择受试者治疗性脑脊髓炎的方法。 在一个实施方案中，本发明提供了基于调节水平的乳酸脱氢酶（LDH）预先选择受试者治疗性脑脊髓炎的方法。 本发明还提供了通过向受试者施用有效量的elesclomol来治疗受试者的癌症的方法，其中受试者具有调节的缺氧水平。 本发明还提供实施本发明方法的试剂盒。
-
5.发明申请HSP90 INHIBITORY COMPOUNDS IN TREATING JAK/STAT SIGNALING-MEDIATED CANCERS 审中-公开HSP90抑制剂治疗JAK / STAT信号传导癌的化合物公开(公告)号：US20140045908A1
公开(公告)日：2014-02-13
申请号：US14001427
申请日：2012-02-24
申请人： Ronald K. Blackman , Kevin P. Foley , David Proia
发明人： Ronald K. Blackman , Kevin P. Foley , David Proia
IPC分类号： A61K31/4196
CPC分类号： A61K31/4196 , A61K31/675
摘要： Methods for treating a subject with cancer mediated through dysregulated, aberrant, or defective JAK/STAT signaling, are provided, comprising determining the level of the JAK/STAT signaling in a sample derived from a subject in need of treatment, wherein the presence of dysregulated, aberrant, or defective JAK/STAT signaling is indicated, administering to the subject an effective amount of a triazolone compound as described herein.
摘要翻译： 提供了通过失调的，异常的或有缺陷的JAK / STAT信号传导介导的患有癌症的受试者的方法，包括确定衍生自需要治疗的受试者的样品中JAK / STAT信号的水平，其中存在失调 ，表示异常或缺陷的JAK / STAT信号传导，向受试者施用有效量的本文所述的三唑酮化合物。
-
6.发明申请PRESELECTION OF SUBJECTS FOR THERAPEUTIC TREATMENT WITH OXYGEN SENSITIVE AGENTS BASED IN HYPOXIC STATUS 审中-公开基于超临界状态的含氧敏感剂代谢治疗方案公开(公告)号：US20140024030A1
公开(公告)日：2014-01-23
申请号：US13895709
申请日：2013-05-16
申请人： Ronald K. Blackman , Vojo Vukovic
发明人： Ronald K. Blackman , Vojo Vukovic
CPC分类号： G01N33/5023 , A61K31/395 , A61K31/4196 , A61K31/436 , A61K31/437 , A61K31/4439 , A61K31/502 , A61K31/506 , A61K31/517 , A61K2039/55 , C07K16/22 , C07K16/2863 , C07K16/32 , C12Q1/6886
摘要： The present invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of hypoxia in cancerous cells in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of lactate dehydrogenase (LDH) in a cell, e.g., a cancerous cell. The invention also provides methods for treating cancer in a subject by administering an effective amount of an agent to the subject, wherein the subject has been selected based on a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention.
摘要翻译： 本发明提供了用于基于受试者的癌细胞中调节的缺氧水平，用药物预处理受试者的方法。 在一个实施方案中，本发明提供了预先选择受试者的方法，所述方法基于在细胞例如癌细胞中基于调节水平的乳酸脱氢酶（LDH）的药剂进行治疗性治疗。 本发明还提供了通过向受试者施用有效量的试剂来治疗受试者中的癌症的方法，其中已经基于调节的缺氧水平来选择受试者。 本发明还提供实施本发明方法的试剂盒。
-
7.发明申请CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A VEGF INHIBITOR 审中-公开使用HSP90抑制化合物和VEGF抑制剂组合的癌症治疗公开(公告)号：US20130156755A1
公开(公告)日：2013-06-20
申请号：US13642064
申请日：2011-04-19
IPC分类号： A61K39/395 , A61K31/4196
CPC分类号： A61K31/4196 , A61K39/395 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical combination comprising a VEGF inhibitor, and an Hsp90 inhibitor according to the following formulae (I) or (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical combinations described herein.
摘要翻译： 包含VEGF抑制剂和根据下式（I）或（Ia）的互变异构体或其药学上可接受的盐的Hsp90抑制剂的药物组合，其中结构式中的变量在本文中定义。 还提供了使用本文所述的药物组合治疗有此需要的个体的增殖性病症的方法。
-
8.发明申请CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR 有权使用HSP90抑制化合物和EGFR抑制剂组合的癌症治疗公开(公告)号：US20130150385A1
公开(公告)日：2013-06-13
申请号：US13642068
申请日：2011-04-19
IPC分类号： A61K31/517 , A61K31/4196
CPC分类号： A61K31/4196 , A61K31/517 , A61K31/675 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical combination comprising an EGFR inhibitor and an Hsp90 inhibitor according to the following formulae (I) or (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof using pharmaceutical combinations disclosed herein.
摘要翻译： 包含EGFR抑制剂和根据下式（I）或（Ia）的互变异构体或其药学上可接受的盐的Hsp90抑制剂的药物组合，其中结构式中的变量在本文中定义。 还提供了使用本文公开的药物组合治疗有需要的受试者的增殖性病症的方法。
-
公开(公告)号：US20120245186A1
公开(公告)日：2012-09-27
申请号：US13501608
申请日：2010-10-19
IPC分类号： A61K31/4196 , A61P35/02 , A61K31/423 , A61P35/00 , A61K31/428 , A61K31/52
CPC分类号： A61K31/337 , A61K31/4196 , A61K45/06 , A61K2300/00
摘要： Disclosed is a method for treating a subject with cancer, comprising administering to the subject an effective amount of paclitaxel or a paclitaxel analogue and an effective amount of a compound represented by the following structural formula: a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the structural formula are defined herein.
摘要翻译： 公开了一种治疗患有癌症的受试者的方法，其包括对受试者施用有效量的紫杉醇或紫杉醇类似物和有效量的由以下结构式表示的化合物：互变异构体或其药学上可接受的盐。 结构式中描述的变量在本文中定义。
-
10.发明申请公开(公告)号：US20140178366A1
公开(公告)日：2014-06-26
申请号：US14109543
申请日：2013-12-17
申请人： Ronald K. Blackman , Vojo Vukovic
发明人： Ronald K. Blackman , Vojo Vukovic
IPC分类号： C07K16/22 , A61K31/4985 , A61K31/517 , G01N33/574 , A61K31/4745 , A61K31/4439 , A61K31/506 , A61K31/502 , A61K31/439 , A61K31/44
CPC分类号： C07K16/22 , A61K31/404 , A61K31/436 , A61K31/439 , A61K31/44 , A61K31/4412 , A61K31/4439 , A61K31/4745 , A61K31/4985 , A61K31/502 , A61K31/506 , A61K31/517 , G01N33/57484
摘要： The present invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of hypoxia in cancerous cells in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of lactate dehydrogenase (LDH) in a cell, e.g., a cancerous cell. The invention also provides methods for treating cancer in a subject by administering an effective amount of an agent to the subject, wherein the subject has been selected based on a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention.
摘要翻译： 本发明提供了用于基于受试者的癌细胞中调节的缺氧水平，用药物预处理受试者的方法。 在一个实施方案中，本发明提供了预先选择受试者的方法，所述方法基于在细胞例如癌细胞中基于调节水平的乳酸脱氢酶（LDH）的药剂进行治疗性治疗。 本发明还提供了通过向受试者施用有效量的试剂来治疗受试者中的癌症的方法，其中已经基于调节的缺氧水平来选择受试者。 本发明还提供实施本发明方法的试剂盒。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.035 秒)